

only as directed to *E. faecalis*, as well as a second group to all claims but only as directed to *B. subtilis*. For example, the combination of Group I and Group III claims would not result in an undue burden on the Examiner. While methods of screening for the ability of a compound to bind to a target are different than methods of screening for the ability of a compound to inhibit a target, in practice these searches will be almost completely identical. Similarly, in the case of all of the claims, searching for the sequence of the gene and protein, as well as searching for the name thereof, will likely comprise the bulk of the search. As such, examining all of the claims simultaneously will not result in an undue burden to the Examiner.


The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment, to Deposit Account No. 16-1445.

A Notice of Allowance is courteously solicited.

Date:

5/12/03

Respectfully submitted,



Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746